Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 13, 2026Annals of Pharmacotherapy

Doravirine/Islatravir: A 2-Drug Regimen for the Treatment of HIV-1 Infection

View Full Paper
Ask AI
Bookmark
Share

Authors

ECElias B. ChahineDKDavid E. KorenRSRafik Samuel

Discussion

Loading...

Member takes

Overview

Review evaluates the efficacy and safety of doravirine/islatravir for treating HIV-1, indicating significant clinical implications.

Key Points

  • This study reviews the efficacy and safety of the doravirine/islatravir regimen for HIV-1 treatment.
  • Included all English-language studies assessing doravirine/islatravir efficacy and safety.
  • Data sourced from clinical trials and conference abstracts.
  • Evaluated three phase 3 clinical trials.
  • Doravirine/islatravir regimen showed effectiveness with a lower islatravir dose of 0.25 mg.
  • The combination was safe, as prior higher doses were linked to reduced lymphocyte and CD4+ T-cell counts.
  • FDA approved doravirine/islatravir for adults who are virologically suppressed without treatment failure.

Cite This Study

Chahine et al. (2026) studied this question.

synapsesocial.com/papers/6a7d76c82b0e0cff3f640779https://doi.org/10.1177/10600280261472079
View Full Paper
Ask AI
Bookmark
Share